Authors: Kollmannsberger C; British Columbia Cancer Agency, Vancouver, Canada. ckollmannsberger@bccancer.bc.ca., Britten CD; Formely With Medical, University of South Carolina, Charleston, SC, USA., Olszanski AJ; Fox Chase Cancer Center, Philadelphia, PA, USA., Walker JA; Formerly With Eli Lilly and Company, Indianapolis, IN, USA., Zang W; Eli Lilly and Company, Indianapolis, IN, USA., Willard MD; Eli Lilly and Company, Indianapolis, IN, USA., Radtke DB; Eli Lilly and Company, Indianapolis, IN, USA., Farrington DL; Formerly With Eli Lilly and Company, Indianapolis, IN, USA., Bell-McGuinn KM; Formerly With Eli Lilly and Company, Indianapolis, IN, USA., Patnaik A; START (South Texas Accelerated Research Therapeutics), San Antonio, USA.

Source: Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1613-1623. Date of Electronic Publication: 2021 Jul 15.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Authors: Lewis JH; Georgetown University Hospital, Washington, DC., Khaldoyanidi SK; Early Development Oncology, Amgen Inc., Thousand Oaks, CA., Britten CD; Early Development Oncology, Amgen Inc., Thousand Oaks, CA., Wei AH; The Alfred Hospital and Monash University, Melbourne, Victoria, Australia., Subklewe M; University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Source: American journal of clinical oncology [Am J Clin Oncol] 2022 Aug 01; Vol. 45 (8), pp. 352-365. Date of Electronic Publication: 2022 Jul 18.

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-453X (Electronic) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE

MeSH Terms: Chemical and Drug Induced Liver Injury*/diagnosis , Chemical and Drug Induced Liver Injury*/etiology , Neoplasms*/drug therapy, Alanine Transaminase/therapeutic use ; Aspartate Aminotransferases/therapeutic use ; Humans

Authors: Stewart MD; Friends of Cancer Research. Electronic address: mstewart@focr.org., McCall B; Genentech, A Member of the Roche Group., Pasquini M; Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research., Yang AS; Xencor., Britten CD; Amgen., Chuk M; Food and Drug Administration., De Claro RA; Food and Drug Administration., George B; Food and Drug Administration., Gormley N; Food and Drug Administration., Horowitz MM; Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research., Kowack E; Xencor., McCoy C; Bristol Myers Squibb., Morrow PK; Amgen., Okoye E; Regeneron Pharmaceuticals., Ricafort R; Bristol Myers Squibb., Rossi J; CERo Therapeutics., Sharon E; National Cancer Institute., Theoret M; Food and Drug Administration., Vegni F; Bristol Myers Squibb., Yu T; Amgen., Allen J; Friends of Cancer Research.

Source: Cytotherapy [Cytotherapy] 2022 Jul; Vol. 24 (7), pp. 742-749. Date of Electronic Publication: 2022 Feb 23.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 100895309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2566 (Electronic) Linking ISSN: 14653249 NLM ISO Abbreviation: Cytotherapy Subsets: MEDLINE

MeSH Terms: Cytokine Release Syndrome*/etiology , Immunotherapy*/adverse effects , Neoplasms*/therapy, Antibodies, Bispecific ; Clinical Trials as Topic ; Humans ; Immunotherapy, Adoptive/adverse effects

Authors: Noel M; Department of Medicine, Division of Hematology/Oncology, University of Rochester Medical Center School of Medicine & Dentistry, Rochester, NY, USA., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ryan DP; MGH Cancer Center, Division of Hematogy-Oncology, Massachusetts General Hospital, Boston, MA, USA., Bullock AJ; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Britten CD; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA., Linehan DC; Department of Surgery, University of Rochester Medical Center School of Medicine & Dentistry, Rochester, NY, USA., Belt BA; Department of Surgery, University of Rochester, Rochester, NY, USA., Gamelin EC; Early Oncology Development and Clinical Research, Pfizer Inc, 219 East 42nd Street, New York, NY, 10017, USA., Ganguly B; Early Oncology Development and Clinical Research, Pfizer Inc, 219 East 42nd Street, New York, NY, 10017, USA.; Lyell Immunopharma Inc, Palo Alto, CA, USA., Yin D; Early Oncology Development and Clinical Research, Pfizer Inc, 219 East 42nd Street, New York, NY, 10017, USA., Joh T; Early Oncology Development and Clinical Research, Pfizer Inc, 219 East 42nd Street, New York, NY, 10017, USA., Jacobs IA; Early Oncology Development and Clinical Research, Pfizer Inc, 219 East 42nd Street, New York, NY, 10017, USA. ira.jacobs@pfizer.com., Taylor CT; Early Oncology Development and Clinical Research, Pfizer Inc, 219 East 42nd Street, New York, NY, 10017, USA., Lowery MA; Trinity St James's Cancer Institute, Trinity College Dublin, Dublin, Ireland.

Source: Investigational new drugs [Invest New Drugs] 2020 Jun; Vol. 38 (3), pp. 800-811. Date of Electronic Publication: 2019 Jul 12.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Authors: Rodon J; Medical Oncology Department, Vall d'Hebrón University Hospital, Barcelona, Spain. jrodon@vhio.net., Pérez-Fidalgo A; INCLIVA Biomedical Research Institute, Valencia, Spain., Krop IE; Dana-Farber Cancer Institute, Boston, MA, USA., Burris H; Sarah Cannon Research Institute, Nashville, TN, USA., Guerrero-Zotano A; Instituto Valenciano de Oncología, Valencia, Spain., Britten CD; Medical University of South Carolina, Charleston, SC, USA., Becerra C; Texas Oncology, Dallas, TX, USA., Schellens J; The Netherlands Cancer Institute, Amsterdam, The Netherlands., Richards DA; Texas Oncology, Dallas, TX, USA., Schuler M; West German Cancer Center, University Hospital Essen, Essen, Germany., Abu-Khalaf M; Thomas Jefferson University, Philadelphia, PA, USA., Johnson FM; MD Anderson Cancer Center, Houston, TX, USA., Ranson M; Manchester University, Manchester, UK., Edenfield J; Greenville Memorial Hospital, Greenville, SC, USA., Silva AP; Novartis Pharma AG, Basel, Switzerland., Hackl W; Novartis Pharma AG, Basel, Switzerland., Quadt C; Novartis Pharma AG, Basel, Switzerland., Demanse D; Novartis Pharma AG, Basel, Switzerland., Duval V; Novartis Pharma AG, Basel, Switzerland., Baselga J; Memorial Sloan Kettering Cancer Center, New York, USA.

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2018 Aug; Vol. 82 (2), pp. 285-298. Date of Electronic Publication: 2018 Jun 07.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol

Authors: Pooler DB; Norris Cotton Cancer Center & Department of Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire., Ness DB; Norris Cotton Cancer Center & Department of Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire., Sarantopoulos J; Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, Texas., Squittieri N; Sun Pharmaceutical Industries, Inc., Princeton, New Jersey., Ravichandran S; Novartis Oncology Clinical Development, East Hanover, New Jersey., Britten CD; Medical University of South Carolina, Charleston, South Carolina., Amaravadi RK; Abramson Cancer Center University of Pennsylvania, Philadelphia, Pennsylvania., Vaishampayan U; Karmanos Cancer Institute, Detroit, Michigan., LoRusso P; Karmanos Cancer Institute, Detroit, Michigan., Shapiro GI; Dana-Farber Cancer Institute, Boston, Massachusetts., Olszanski AJ; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Perez R; University of Kansas Medical Center, Fairway, Kansas., Gutierrez M; Hackensack University Medical Center, Hackensack, NH, USA., O'Rourke MA; Prisma Health Upstate Cancer Institute, Greenville, South Carolina., Chung V; City of Hope National Medical Center, Duarte, California., Lee JJ; University of Pittsburgh Cancer Institute, Pittsburg, Pennsylvania., Lewis LD; Norris Cotton Cancer Center & Department of Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.

Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Mar; Vol. 87 (3), pp. 1291-1302. Date of Electronic Publication: 2020 Aug 20.

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

MeSH Terms: Neoplasms*/drug therapy , Warfarin*, Administration, Oral ; Area Under Curve ; Biphenyl Compounds ; Bupropion/therapeutic use ; Drug Interactions ; Humans ; Pyridines

Authors: Wainberg ZA; David Geffen School of Medicine at UCLA, 2020 Santa Monica Blvd, Suite 600, Los Angeles, CA, 90404, USA. ZWainberg@mednet.ucla.edu., Alsina M; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Vall d'Hebron 119-129, 08035, Barcelona, Spain., Soares HP; Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA., Braña I; Princess Margaret Cancer Centre, 610 University Avenue, Toronto, M5G 2M9, Canada., Britten CD; Medical University of South Carolina, 39 Sabin St., MSC 635, Charleston, SC, 29425, USA., Del Conte G; IRCCS Ospedale S. Raffaele, via Olgettina 60, 20132, Milan, Italy., Ezeh P; Pfizer Oncology, 300 Technology Square, Cambridge, MA, 02139, USA., Houk B; Pfizer Oncology, 10646 Science Center Drive, San Diego, CA, 92121, USA., Kern KA; Pfizer Oncology, 10646 Science Center Drive, San Diego, CA, 92121, USA., Leong S; University of Colorado Denver School of Medicine, 13001 E 17th Place, Aurora, CO, 80045, USA., Pathan N; Pfizer Oncology, 10646 Science Center Drive, San Diego, CA, 92121, USA., Pierce KJ; Pfizer Oncology, 558 Eastern Point Road, Groton, CT, 06340, USA., Siu LL; Princess Margaret Cancer Centre, 610 University Avenue, Toronto, M5G 2M9, Canada., Vermette J; Pfizer Oncology, 300 Technology Square, Cambridge, MA, 02139, USA., Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Vall d'Hebron 119-129, 08035, Barcelona, Spain.

Source: Targeted oncology [Target Oncol] 2017 Dec; Vol. 12 (6), pp. 775-785.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Authors: Diamond JR; University of Colorado Cancer Center, 12801 E. 17th Avenue, Mailstop 8117, Aurora, CO, 80045, USA. Jennifer.diamond@ucdenver.edu., Goff B; University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA., Forster MD; Sarah Cannon Research Institute UK, London, UK., Bendell JC; Sara Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Britten CD; Medical University of South Carolina, Charleston, SC, USA., Gordon MS; Pinnacle Oncology Hematology, Scottsdale, AZ, USA., Gabra H; Imperial College London, London, UK., Waterhouse DM; Oncology Hematology Care, Cincinnati, OH, USA., Poole M; MEI Pharma, San Diego, CA, USA., Ross Camidge D; University of Colorado Cancer Center, 12801 E. 17th Avenue, Mailstop 8117, Aurora, CO, 80045, USA., Hamilton E; Sara Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Moore KM; Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Source: Investigational new drugs [Invest New Drugs] 2017 Oct; Vol. 35 (5), pp. 627-633. Date of Electronic Publication: 2017 Mar 10.

Publication Type: Clinical Trial, Phase I; Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Authors: Mehrotra S; Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA. mehrotr@musc.edu.; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA. mehrotr@musc.edu.; Present address: Gibbs Cancer Center and Research Institute, 380 Serpentine Drive, Spartanburg, SC, 29303, USA. mehrotr@musc.edu., Britten CD; Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA., Chin S; Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.; Present address: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA., Garrett-Mayer E; Departmet of Population Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA., Cloud CA; Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA., Li M; Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA., Scurti G; Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.; Department of Surgery, Loyola University Medical Center, Maywood, IL, 60153, USA., Salem ML; Center of Excellence in Cancer Research and Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt., Nelson MH; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA., Thomas MB; Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.; Present address: Gibbs Cancer Center and Research Institute, 380 Serpentine Drive, Spartanburg, SC, 29303, USA., Paulos CM; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA., Salazar AM; Oncovir Inc., 3202 Cleaveland Avenue NW, Washington, DC, 20008, USA., Nishimura MI; Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.; Department of Surgery, Loyola University Medical Center, Maywood, IL, 60153, USA., Rubinstein MP; Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA., Li Z; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA., Cole DJ; Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA. coledj@musc.edu.; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA. coledj@musc.edu.

Source: Journal of hematology & oncology [J Hematol Oncol] 2017 Apr 07; Vol. 10 (1), pp. 82. Date of Electronic Publication: 2017 Apr 07.

Publication Type: Clinical Trial; Journal Article

Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

Authors: Meystre SM; Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, United States; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, United States. Electronic address: meystre@musc.edu., Heider PM; Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, United States., Kim Y; Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, United States., Aruch DB; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, United States., Britten CD; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, United States.

Source: International journal of medical informatics [Int J Med Inform] 2019 Sep; Vol. 129, pp. 13-19. Date of Electronic Publication: 2019 May 23.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Science Ireland Ltd Country of Publication: Ireland NLM ID: 9711057 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8243 (Electronic) Linking ISSN: 13865056 NLM ISO Abbreviation: Int J Med Inform Subsets: MEDLINE

MeSH Terms: Eligibility Determination*, Automation ; Breast Neoplasms ; Data Warehousing ; Databases, Factual ; Female ; Humans ; Machine Learning ; Male ; Middle Aged ; Natural Language Processing ; Patient Selection ; Workload

Authors: Sharma S; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Rm 3360, Salt Lake City, UT, 84112, USA, sunil.sharma@hci.utah.edu., Britten CD, Mortimer J, Kulkarni S, Quinlan M, Liu A, Scott JW, George D

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2014 Oct; Vol. 74 (4), pp. 867-74. Date of Electronic Publication: 2014 Sep 06.

Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Authors: Britten CD; UCLA Medical Center, Los Angeles, CA, USA, britten@musc.edu., Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K, Wainberg ZA, LoRusso PM

Source: Investigational new drugs [Invest New Drugs] 2014 Jun; Vol. 32 (3), pp. 510-7. Date of Electronic Publication: 2014 Jan 07.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Authors: von Mehren M; Fox Chase Cancer Center, Philadelphia, PA, USA, Margaret.vonMehren@fccc.edu., Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S

Source: Investigational new drugs [Invest New Drugs] 2014 Jun; Vol. 32 (3), pp. 518-25. Date of Electronic Publication: 2014 Jan 24.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Authors: Garon EB; Division of Hematology/Oncology, Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA, USA, egaron@mednet.ucla.edu., Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ

Source: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2014 Mar; Vol. 140 (3), pp. 443-52. Date of Electronic Publication: 2014 Jan 18.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE

Authors: Britten CD; Division of Hematology/Oncology, Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Clinical Science Building, Suite 903, Charleston, SC 29425, USA. britten@musc.edu

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2013 Jun; Vol. 71 (6), pp. 1395-409. Date of Electronic Publication: 2013 Feb 27.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Authors: Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Ellerton J; Nevada Cancer Research Foundation, Las Vegas, NV, USA., Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Agrawal M; Associates in Oncology, Rockville, MD, USA., Gordon M; Pinnacle Oncology Hematology, A Division of Arizona Center for Cancer Care, HonorHealth Research Institute Clinical Trials Program at the Virginia G Piper Cancer Center, University of Arizona College of Medicine, Phoenix, Scottsdale, AZ, USA., Aljumaily R; Oklahoma University Medical Center, Oklahoma City, OK, USA., Britten CD; Medical University of South Carolina, Division of Hematology/Oncology, Charleston, SC, USA., Dirix L; Sint-Augustinus Hospital, Oncology Center, Medical Oncology, Antwerpen, Belgium., Lee KW; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea., Taylor M; Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA., Schöffski P; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Wang D; Henry Ford Hospital, Detroit, MI, USA., Ravaud A; Groupe Hospitalier Saint André, Hôpital Saint André, CHU de Bordeaux, Bordeaux Cedex, France., Gelb AB; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA., Xiong J; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA., Rosen G; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA., Gulley JL; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Apolo AB; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Magnuson Clinical Center, Bethesda, MD, USA. Electronic address: andrea.apolo@nih.gov.

Source: The Lancet. Oncology [Lancet Oncol] 2018 Jan; Vol. 19 (1), pp. 51-64. Date of Electronic Publication: 2017 Dec 05.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents, Immunological/*therapeutic use , Carcinoma/*drug therapy , Organoplatinum Compounds/*therapeutic use , Platinum Compounds/*therapeutic use , Urologic Neoplasms/*drug therapy , Urothelium/*drug effects, Aged ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological/adverse effects ; Asia ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Carcinoma/immunology ; Carcinoma/mortality ; Carcinoma/secondary ; Disease-Free Survival ; Europe ; Female ; Humans ; Male ; Middle Aged ; Organoplatinum Compounds/adverse effects ; Platinum Compounds/adverse effects ; Time Factors ; Treatment Failure ; United States ; Urologic Neoplasms/immunology ; Urologic Neoplasms/mortality ; Urologic Neoplasms/pathology ; Urothelium/immunology ; Urothelium/pathology

Authors: Gomes AS; 1 Department of Radiological Sciences, Interventional Radiology, and Department of Medicine, The David Geffen School of Medicine at the University of California at Los Angeles, Ronald Reagan UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA 90095., Monteleone PA; 1 Department of Radiological Sciences, Interventional Radiology, and Department of Medicine, The David Geffen School of Medicine at the University of California at Los Angeles, Ronald Reagan UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA 90095., Sayre JW; 2 The UCLA Jonathan and Karin Fielding School of Public Health at the University of California at Los Angeles, Los Angeles, CA., Finn RS; 3 Department of Medicine, Hematology and Oncology, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA., Sadeghi S; 3 Department of Medicine, Hematology and Oncology, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA., Tong MJ; 4 Department of Medicine, Surgery, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA., Britten CD; 5 Department of Medicine, Hematology and Oncology, Medical University of South Carolina, Charleston, SC., Busuttil RW; 4 Department of Medicine, Surgery, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA.

Source: AJR. American journal of roentgenology [AJR Am J Roentgenol] 2017 Oct; Vol. 209 (4), pp. 722-732. Date of Electronic Publication: 2017 Jul 13.

Publication Type: Comparative Study; Journal Article

Journal Info: Publisher: American Roentgen Ray Society Country of Publication: United States NLM ID: 7708173 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-3141 (Electronic) Linking ISSN: 0361803X NLM ISO Abbreviation: AJR Am J Roentgenol Subsets: MEDLINE

MeSH Terms: Drug Carriers* , Microspheres*, Antibiotics, Antineoplastic/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Carcinoma, Hepatocellular/*mortality , Carcinoma, Hepatocellular/*therapy , Chemoembolization, Therapeutic/*methods , Doxorubicin/*administration & dosage , Liver Neoplasms/*mortality , Liver Neoplasms/*therapy, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Catheterization ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate ; Time Factors ; Young Adult

Authors: Wallace K; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC. Electronic address: wallack@musc.edu., DeToma A; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC., Lewin DN; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC., Sun S; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC., Rockey D; Department of Medicine, Medical University of South Carolina, Charleston, SC., Britten CD; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC., Wu JD; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC., Ba A; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC., Alberg AJ; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC., Hill EG; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.

Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2017 Sep; Vol. 16 (3), pp. 178-186. Date of Electronic Publication: 2016 Dec 07.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE

MeSH Terms: Health Status Disparities*, Adenocarcinoma/*epidemiology , Colorectal Neoplasms/*epidemiology, Adolescent ; Adult ; Black or African American ; Aged ; Aged, 80 and over ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; SEER Program ; White People ; Young Adult

Authors: Britten CD; Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina., Garrett-Mayer E; Department of Population Sciences, Medical University of South Carolina, Charleston, South Carolina., Chin SH; Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina., Shirai K; Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina., Ogretmen B; Department of Biochemistry & Molecular Biology, Medical University of South Carolina, Charleston, South Carolina., Bentz TA; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Brisendine A; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Anderton K; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Cusack SL; Apogee Biotechnology Corporation, Hummelstown, Pennsylvania., Maines LW; Apogee Biotechnology Corporation, Hummelstown, Pennsylvania., Zhuang Y; Apogee Biotechnology Corporation, Hummelstown, Pennsylvania., Smith CD; Apogee Biotechnology Corporation, Hummelstown, Pennsylvania. cdsmith@apogee-biotech.com., Thomas MB; Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Aug 15; Vol. 23 (16), pp. 4642-4650. Date of Electronic Publication: 2017 Apr 18.

Publication Type: Clinical Trial, Phase I; Journal Article

Journal Info: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

MeSH Terms: Adamantane/*analogs & derivatives , Neoplasms/*drug therapy , Phosphotransferases (Alcohol Group Acceptor)/*antagonists & inhibitors , Pyridines/*therapeutic use, Adamantane/adverse effects ; Adamantane/therapeutic use ; Adult ; Aged ; Dose-Response Relationship, Drug ; Fatigue/chemically induced ; Female ; Humans ; Male ; Middle Aged ; Nausea/chemically induced ; Neoplasms/pathology ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Pyridines/adverse effects ; Treatment Outcome ; Vomiting/chemically induced ; Young Adult

Authors: Apolo AB; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Infante JR; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Balmanoukian A; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Patel MR; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Wang D; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Kelly K; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Mega AE; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Britten CD; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Ravaud A; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Mita AC; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Safran H; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Stinchcombe TE; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Srdanov M; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Gelb AB; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Schlichting M; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Chin K; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany., Gulley JL; Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Jul 01; Vol. 35 (19), pp. 2117-2124. Date of Electronic Publication: 2017 Apr 04.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal/*administration & dosage , Urologic Neoplasms/*drug therapy, Aged ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Cohort Studies ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Urologic Neoplasms/immunology